X4 Pharmaceuticals is a clinical-stage oncology company developing oral small molecule CXCR4 antagonists for the treatment.
X4 Pharmaceuticals has raised $155.3M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2025.
X4 Pharmaceuticals's investors include New Enterprise Associates, Lumira Ventures, Bain Capital Life Sciences, OrbiMed, Cormorant Asset Management.
X4 Pharmaceuticals is headquartered in Cambridge, United States.
X4 Pharmaceuticals is a clinical-stage oncology company developing oral small molecule CXCR4 antagonists for the treatment.
X4 Pharmaceuticals is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"X4 Pharmaceuticals — Funding & Investors." VCBacked, October 24, 2025, https://www.vcbacked.co/company/x4-pharmaceuticals. Accessed July 19, 2026.
VCBacked. (2025). X4 Pharmaceuticals — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/x4-pharmaceuticals
{{cite web |title=X4 Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/x4-pharmaceuticals |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated